Nanalysis Taps Industry Vets for Board to Drive Growth Strategy

CALGARY, AB – May 01, 2026 – Nanalysis Scientific Corp. (TSXV: NSCI), a company making its mark with portable nuclear magnetic resonance (NMR) technology, has announced a significant strategic overhaul of its Board of Directors. The appointment of three industry heavyweights—Jonathan Ladd, Dr. Werner Maas, and Steve Feick—signals a clear and aggressive intent to accelerate growth, scale its global footprint, and fortify its dual-pronged strategy of product innovation and high-value services.

The transition, effective May 1, 2026, sees the departure of board members Martin Burian and Jennifer Stubbs, who were thanked for their service. The incoming directors bring a formidable combination of experience in scaling technology firms, deep domain expertise in the highly specialized NMR market, and sophisticated capital management, precisely aligning with the company's stated ambitions.

"We are pleased to welcome Jonathan, Werner, and Steve," stated Sean Krakiwsky, Chief Executive Officer of Nanalysis. "Their collective experience across instrumentation, global commercialization, and capital allocation will support the Company as we focus on scaling our core NMR platform and executing on our services growth strategy."

This board refreshment is more than a routine governance update; it appears to be a calculated maneuver to equip Nanalysis with the leadership needed to navigate its next and most ambitious phase of corporate evolution.

A Board Built for Strategic Expansion

The composition of the new board appointments reads like a strategic wish list for a company at Nanalysis's inflection point. Each new member brings a distinct, yet complementary, skill set directly addressing the company's key growth pillars: scaling its core technology, expanding its commercial reach, and intelligently deploying capital to fuel these initiatives.

Dr. Werner Maas brings an almost unparalleled level of expertise in the company's core market. As the former President of Bruker BioSpin Corporation, a global leader in high-performance scientific instruments including NMR spectrometers, his presence on the board is a powerful endorsement and a strategic coup. His intimate knowledge of the competitive landscape, customer needs, and commercialization pathways for NMR technology provides Nanalysis with invaluable insider perspective. Now serving as CEO of Hudson Lab Automation, his expertise extends to the broader laboratory and analytical instrumentation ecosystem.

Complementing this deep technical knowledge is Jonathan Ladd, a seasoned executive renowned for scaling technology companies to global success. His tenure as CEO of NovAtel Inc., which he led from a promising GPS technology firm to its successful acquisition by industrial technology giant Hexagon AB, provides a clear blueprint for the kind of growth Nanalysis aspires to. His experience in capital markets, corporate governance, and executing strategic plans within advanced technology sectors will be critical as Nanalysis seeks to expand its market share and enhance shareholder value.

Rounding out the trio is Steve Feick, President of Manvest Inc., the private equity arm of the Mancal Group. Feick represents the voice of sophisticated capital and long-term strategic investment. With a track record of nurturing a diverse portfolio of companies in technology, energy, and data analytics, he brings a rigorous, investor-focused discipline to the board. His expertise in capital allocation and governance ensures that the company's growth ambitions will be supported by a sound, sustainable financial strategy.

Deepening Expertise in a Niche-Tech World

The strategic value of the new appointments becomes even clearer when examining their individual track records. They are not just generalist business leaders; they are specialists whose careers have been defined by success in arenas directly relevant to Nanalysis's operations.

Dr. Maas's experience is particularly noteworthy. Bruker is a dominant force in the NMR market, traditionally focused on large, high-field systems. Nanalysis's niche is in portable, benchtop NMR spectrometers—a segment democratizing access to this powerful analytical technique. Dr. Maas's decision to join the board of a smaller, innovative player suggests a strong belief in the disruptive potential of portable NMR. His understanding of where the market is heading and how to commercialize scientific instruments on a global scale—honed also during his time at Mettler Toledo—will be instrumental in helping Nanalysis outmaneuver larger competitors and open new markets in pharma, biotech, food science, and materials research.

Meanwhile, Jonathan Ladd's background at NovAtel offers a compelling parallel. He successfully navigated a high-tech, B2B market, scaling a company's technology into a globally recognized standard. This experience is directly transferable to Nanalysis's challenge of making its portable NMR spectrometers an indispensable tool in labs and industrial settings worldwide. His current advisory and board roles with several technology startups, including in agriculture and infrastructure, also indicate a continued focus on commercializing cutting-edge innovation.

Steve Feick’s role at Manvest, where he managed a portfolio through growth and successful exits, provides the crucial oversight needed to ensure expansion is both ambitious and prudent. His experience as a former entrepreneur who understands operational realities, combined with his current role as a strategic investor, creates a balanced perspective that is vital for a growing public company. He is tasked with helping the board make the tough decisions about where to invest for maximum long-term return.

Balancing Core Products with a Growing Services Powerhouse

While Nanalysis is known for its innovative NMR products, a significant and growing part of its business is its services division. This division is anchored by a landmark $160 million long-term contract with the Canadian Air Transport Security Authority (CATSA) to maintain security scanners at over 80 airports across Canada. This contract is a game-changer, providing a stable, predictable, and substantial revenue stream that is the envy of many technology hardware companies.

This services revenue provides a powerful financial foundation, de-risking the company's overall business model. It can fund ongoing research and development for the NMR product line, finance marketing and sales expansion, and provide stability through economic cycles. The board's new composition is well-suited to oversee this dual strategy. Jonathan Ladd's experience in scaling global operations is as relevant to a services division as it is to a product-based one. Steve Feick's expertise in capital allocation will be key in deciding how to reinvest the profits from the services division to drive growth across the entire company.

The challenge and opportunity for Nanalysis is to execute on both fronts simultaneously—to continue innovating and leading in the portable NMR space while efficiently managing and expanding its lucrative services contracts. The new board's collective experience in technology scaling, financial strategy, and specific market knowledge provides a robust governance framework to meet this challenge head-on, transforming Nanalysis from a promising technology developer into a diversified and resilient scientific instrumentation and services company.